Clark LC, Combs GF, Turnbull BW, Slate EH, Chalker DK, Chow J, Davis LS, Glover RA, Graham GF, Gross EG, et al: Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA. 1996, 276: 1957-1963. 10.1001/jama.276.24.1957.
Ip C, Birringer M, Block E, Kotrebai M, Tyson JF, Uden PC, Lisk DJ: Chemical speciation influences comparative activity of selenium-enriched garlic and yeast in mammary cancer prevention. J Agric Food Chem. 2000, 48: 2062-2070. 10.1021/jf000051f.
Ip C, Lisk DJ, Thompson HJ: Selenium-enriched garlic inhibits the early stage but not the late stage of mammary carcinogenesis. Carcinogenesis. 1996, 17: 1979-1982.
Lu J, Pei H, Ip C, Lisk DJ, Ganther H, Thompson HJ: Effect on an aqueous extract of selenium-enriched garlic on in vitro markers and in vivo efficacy in cancer prevention. Carcinogenesis. 1996, 17: 1903-1907.
Ip C, Thompson HJ, Ganther HE: Selenium modulation of cell proliferation and cell cycle biomarkers in normal and premalignant cells of the rat mammary gland. Cancer Epidemiol Biomarkers Prev. 2000, 9: 49-54.
Ip C, Thompson HJ, Zhu Z, Ganther HE: In vitro and in vivo studies of methylseleninic acid: evidence that a monomethylated selenium metabolite is critical for cancer chemoprevention. Cancer Res. 2000, 60: 2882-2886.
Sinha R, Kiley SC, Lu JX, Thompson HJ, Moraes R, Jaken S, Medina D: Effects of methylselenocysteine on PKC activity, cdk2 phosphorylation and gadd gene expression in synchronized mouse mammary epithelial tumor cells. Cancer Lett. 1999, 146: 135-145. 10.1016/S0304-3835(99)00250-5.
Sinha R, Medina D: Inhibition of cdk2 kinase activity by methylselenocysteine in synchronized mouse mammary epithelial tumor cells. Carcinogenesis. 1997, 18: 1541-1547. 10.1093/carcin/18.8.1541.
Unni E, Singh U, Ganther HE, Sinha R: Se-methylselenocysteine activates caspase-3 in mouse mammary epithelial tumor cells in vitro. Biofactors. 2001, 14: 169-177.
Sinha R, Unni E, Singh U, Koul D, Yung WKA: Se-methylselenocysteine inhibits phosphatidylinositol 3-kinase pathway in mouse mammary epithelial tumor cells [abstract]. Proc Am Assoc Cancer Res. 2003, 44: s887-
Tsitsiloni OE, Stiakakis J, Koutselinis A, Gogas J, Markopoulos C, Yialouris P, Bekris S, Panoussopoulos D, Kiortsis V, Voelter W, et al: Expression of alpha-thymosins in human tissues in normal and abnormal growth. Proc Natl Acad Sci USA. 1993, 90: 9504-9507.
Bargou RC, Jurchott K, Wagener C, Bergmann S, Metzner S, Bommert K, Mapara MY, Winzer KJ, Dietel M, Dorken B, et al: Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression. Nat Med. 1997, 3: 447-450.
Janz M, Harbeck N, Dettmar P, Berger U, Schmidt A, Jurchott K, Schmitt M, Royer HD: Y-box factor YB-1 predicts drug resistance and patient outcome in breast cancer independent of clinically relevant tumor biologic factors HER2, uPA and PAI-1. Int J Cancer. 2002, 97: 278-282. 10.1002/ijc.1610.
Ema M, Suzuki M, Morita M, Hirose K, Sogawa K, Matsuda Y, Gotoh O, Saijoh Y, Fujii H, Hamada H, et al: cDNA cloning of a murine homologue of Drosophila single-minded, its mRNA expression in mouse development, and chromosome localization. Biochem Biophys Res Commun. 1996, 218: 588-594. 10.1006/bbrc.1996.0104.
Mahley RW: Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science. 1988, 240: 622-630.
Denhardt DT, Guo X: Osteopontin: a protein with diverse functions. FASEB J. 1993, 7: 1475-1482.
Senger DR, Perruzzi CA, Papadopoulos A: Elevated expression of secreted phosphoprotein I (osteopontin, 2ar) as a consequence of neoplastic transformation. Anticancer Res. 1989, 9: 1291-1299.
Medina D: Preneoplastic lesions in mouse mammary tumorigenesis. In Methods in Cancer Research. Edited by: Busch H. 1973, New York: Academic Press, 3-53.
Said TK, Bonnette S, Medina D: Immortal, non-tumourigenic mouse mammary outgrowths express high levels of cyclin B1 and activation of cyclin B1/cdc2 kinase. Cell Prolif. 1996, 29: 623-639.
Sinha R, Unni E, Ganther HE, Medina D: Methylseleninic acid, a potent growth inhibitor of synchronized mouse mammary epithelial tumor cells in vitro. Biochem Pharmacol. 2001, 61: 311-317. 10.1016/S0006-2952(00)00545-1.
Katagiri YU, Sleeman J, Fujii H, Herrlich P, Hotta H, Tanaka K, Chikuma S, Yagita H, Okumura K, Murakami M, et al: CD44 variants but not CD44s cooperate with β1-containing integrins to permit cells to bind to osteopontin independently of arginine-glycine-aspartic acid, thereby stimulating cell motility and chemotaxis. Cancer Res. 1999, 59: 219-226.
Ip C, Dong Y: Methylselenocysteine modulates proliferation and apoptosis biomarkers in premalignant lesions of the rat mammary gland. Anticancer Res. 2001, 21: 863-867.
El-Bayoumy K, Narayanan BA, Desai DH, Narayanan NK, Pittman B, Amin SG, Schwartz J, Nixon DW: Elucidation of molecular targets of mammary cancer chemoprevention in the rat by organoselenium compounds using cDNA microarray. Carcinogenesis. 2003, 24: 1505-1514. 10.1093/carcin/bgg103.
Jiang C, Jiang W, Ip C, Ganther H, Lu J: Selenium-induced inhibition of angiogenesis in mammary cancer at chemopreventive levels of intake. Mol Carcinog. 1999, 26: 213-225. 10.1002/(SICI)1098-2744(199912)26:4<213::AID-MC1>3.0.CO;2-Z.
Medina D, Lane HW: Stage specificity of selenium-mediated inhibition of mouse mammary tumorigenesis. Biol Trace Element Res. 1983, 5: 297-306.
Lane HW, Medina D, Wolfe LG: Proposed mechanisms for selenium-inhibition of mammary tumorigenesis. In Vivo. 1989, 3: 151-160.
Sharp JA, Sung V, Slavin J, Thompson EW, Henderson MA: Tumor cells are the source of osteopontin and bone sialoprotein expression in human breast cancer. Lab Invest. 1999, 79: 869-877.
Zheng DQ, Woodard AS, Tallini G, Languino LR: Substrate specificity of αvβ3 integrin-mediated cell migration and phosphatidylinositol 3-kinase/AKT pathway activation. J Biol Chem. 2000, 275: 24565-24574. 10.1074/jbc.M002646200.
Gardner HA, Berse B, Senger DR: Specific reduction in osteopontin synthesis by antisense RNA inhibits the tumorigenicity of transformed Rat1 fibroblasts. Oncogene. 1994, 9: 2321-2326.
Ip C: Lessons from basic research in selenium and cancer prevention. J Nutr. 1998, 128: 1845-1854.
Ip C, Ganther HE: Comparison of selenium and sulfur analogs in cancer prevention. Carcinogenesis. 1992, 13: 1167-1170.
Wang Z, Jiang C, Lu J: Induction of caspase-mediated apoptosis and cell-cycle G1 arrest by selenium metabolite methylselenol. Mol Carcinog. 2002, 34: 113-120. 10.1002/mc.10056.
Zhu Z, Jiang W, Ganther HE, Ip C, Thompson HJ: In vitro effects of Se-allylselenocysteine and Se-propylselenocysteine on cell growth, DNA integrity, and apoptosis. Biochem Pharmacol. 2000, 60: 1467-1473. 10.1016/S0006-2952(00)00461-5.
Felding-Habermann B, Ruggeri ZM, Cheresh DA: Distinct biological consequences of integrin αvβ3-mediated melanoma cell adhesion to fibrinogen and its plasmic fragments. J Biol Chem. 1992, 267: 5070-5077.